Your session is about to expire
← Back to Search
SurVaxM + Temozolomide for Glioblastoma (SURVIVE Trial)
SURVIVE Trial Summary
This trial is testing whether adding SurVaxM to temozolomide chemotherapy helps people with newly diagnosed glioblastoma live longer than temozolomide chemotherapy alone.
SURVIVE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSURVIVE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SURVIVE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I was enrolled in the study within 4 months after my surgery.I have had a second brain surgery for my tumor after undergoing chemotherapy and radiation.I cannot have MRI scans or use gadolinium contrast.I am able to care for myself but may not be able to do active work.I am HIV positive or have an AIDS-related illness.I have had carmustine wafers surgically implanted.My cancer did not worsen after my last treatment.I do not have a serious illness or infection that could interfere with treatment.My brain cancer has come back or gotten worse.I have had tuberculosis or a similar disease in the past.I have been treated with bevacizumab.I am 18 years old or older.I have chosen to undergo Optune therapy.I have had cancer before, but it was successfully treated.I received a unique radiation treatment for my brain cancer.I cannot take temozolomide due to health reasons.My cancer is not glioblastoma.I have been treated with chemotherapy or experimental drugs before.I do not have any health issues that would prevent me from taking the study drug or undergoing procedures.I do not have any ongoing bleeding or conditions that increase my risk of bleeding.My brain cancer affects multiple areas or specific parts of my brain.I have received immunotherapy for my brain tumor.I have been diagnosed with glioblastoma in my brain.I completed radiation therapy with TMZ following the Stupp protocol.I am taking 4 mg or less of dexamethasone daily.My tumor has been tested for the IDH-1 mutation.
- Group 1: Arm A
- Group 2: Arm B
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are enrolled in this experiment at its maximum capacity?
"MimiVax, LLC is responsible for the oversight of this trial which requires 265 eligible patients to proceed. Participants can be found in locations such as Dana Farber Cancer Institute (Boston), and University of California (San Francisco)."
Are there still possibilities to join this research initiative?
"Affirmative. Clinicaltrials.gov has information that this clinical experiment is currently recruiting participants, with the initial posting dating back to November 18th 2021 and most recent modification on August 23rd 2022. A total of 265 patients are sought for enrolment across 11 locations."
Where are the sites offering this clinical trial?
"The trial is being conducted in 11 locations, such as the Dana Farber Cancer Institute of Boston and Miami Cancer Institute of Miami. Additionally, there are 8 other sites across the United States that are taking part in this study."
To what degree is Arm A regarded as secure for individuals?
"The safety of Arm A is rated a 2, as it has been through Phase 2 trials which have demonstrated some assurance of safety but not efficacy."
Share this study with friends
Copy Link
Messenger